Next Phase Newsletter

The company was established as the pharmaceutical arm of a Japanese firm. The firm has a US licensing and clinical development office. The firm also has a Japan-based sales division. The pharma is seeking to form partnerships and in-licensing relationships regarding early stage assets in its key indication areas. These partnerships are highly flexible, and may involve the pharma contributing personnel, sharing studies and research tools, or providing research expense funding.

The pharma is interested in early-stage, first-in-class, orally active small molecule NCEs. The firm seeks assets in the following key areas: Metabolic / Cardiovascular Diseases (NASH, Heart failure (HFrEF, HFpEF, Hypertrophic cardiomyopathy), Diabetic Retinopathy / Diabetic Macular Edema, Chronic Kidney Disease, Sarcopenia), Autoimmune Diseases (Multiple Sclerosis, Lupus, IBD), CNS disorders (Alzheimer’s Disease, Schizophrenia). As well as drugs, the pharma is interested in drug targets in these disease areas. The firm is open to forming partnerships regarding very early stage assets, at or prior to the lead optimization phase. For in-licensing for the Japan market, the company is focused on renal diseases, dermatology and allergic diseases. The compay also invests in drug discovery technologies and research tools such as: technologies related to translational research using cell culture, isolated cellular organelles and related mechanisms; HTS technologies; protein structure analysis; chemical biology, chemical synthesis, and chemical libraries; biophysical tools; in silico technologies; biomarkers and bioinformatics screening, biomarker research, and compound libraries.

The company has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a Venture Capital company founded in 1996 and based in Menlo Park, California. The firm has raised 3 funds to date and is currently investing out of its 3rd that closed at $20M. The firm makes primarily equity investments ranging from $250,000 to $5 million over the lifetime of the investment, with $100K-$500K as an initial investment. The firm has closeting term relationships with several large Japanese medical technology corporations and also looks for ventures that they can introduce into the Japanese market. The firm prefers to invest in companies located in the West coast if the US, although they are also open to review opportunities in North America.

The firm is looking for seed and venture-stage medical and diagnostic device companies. In these areas, the firm is most interested in single use therapeutic devices. The preferred regulatory pathway is a 510(k) submission, but PMA applications are also considered. Sectors with the most interest would be interventional cardiovascular and neurovascular devices, less invasive surgical instrumentation, and point of care diagnostics. The firm remains open-minded to other types of devices and indications as well.

The firm looks for professionalism in a venture’s management team and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat in portfolio companies, however they look to add value by developing corporate partnerships in Japan at the appropriate time.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A new founded US fund of an Asia-based healthcare-focused venture capital firm. The firm seeks to make equity investments into early-stage life science companies. The sweet spot is seed to series B and the typical check size ranges from $5 – $10 million USD. The firm focuses on US, Canada or EU based companies. The firm prefers to co-invest or syndicate with other well-known investors.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics and Medical Technology. Digital Health and purely technology companies are less of interest.

The firm is open to work will entrepreneurs with all experience levels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global investor, headquartered in Europe that was previously focused on oncology has expanded their investments to genetic diseases with its new fund. The firm makes selective investments in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. Typically, the firm invests in incorporated companies from seed stage onwards. The investment size will vary, and it can invest $25-30M over the lifetime of the companies. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies and therapeutics targeting genetic diseases, and is open to all types of therapeutic modalities and all indications relevant to those spaces, including platform technologies. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Project will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of the portfolio companies. To this end, the firm has several experts in oncology and genetic diseases, intellectual property and drug development on the investment team and available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm based in the USA is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor.

The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data.

The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring to fund clinical trials and regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm based in USA manages 5 funds. With the latest fund, the firm looks to provide up to $3-4 million of preferred equity capital in the initial round and up to $6-8 million over the life of the investment. The firm generally looks for companies with lead assets that can reach a high value inflection point in 3-4 years. The firm will consider companies in North America.

The firm is currently looking for companies developing Therapeutics and Medical Technology. Within therapeutics which is the firms primary focus, companies with an asset anywhere from preclinical with positive animal data to Phase II will be considered. The firm is generally open to all technology types and indications with the exception of wound care and psychiatry. Within devices, the firm is currently looking for market approved product with early revenue; however, devices are not an investment priority at present. The firm is looking for companies targeting true un-met medical needs where either no treatment currently exists or the existing standard of care is wrought with side-effects and other impediments to quality care.

The firm does not have any specific requirement for a firm’s management team although they are an active investor looking to take a seat on the company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund of a global firm that provides software-based services to multiple industries, including healthcare and the life sciences does both venture investing and forms strategic partnerships with companies that are aligned with the firm’s current or future services. As an investor, the firm will generally invest between $200K-3M in seed-series A rounds. For partnerships, the firm is looking for companies looking to scale, potentially working in concert to build clients. The firm will invest and partner globally.

The firm invests in companies developing software-based technologies. Examples of the firm’s services include software for healthcare, such as hospital automation and clinical workflow, as well as virtual care and medical adherence, among others. In the life sciences space, the firm is interested in technologies such as software for connected devices, AI/ML platforms for drug discovery, as well as cell or gene therapies, or decentralized clinical trials, as examples.

The firm is only interested in companies that represent a strategic fit, either for currently offered services, or for complementary services that could expand the firm’s portfolio of services.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.